Standout Papers

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gast... 2011 2026 2016 2021 421
  1. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) (2011)
    Peter Thuss‐Patience, Albrecht Kretzschmar et al. European Journal of Cancer

Immediate Impact

3 from Science/Nature 129 standout
Sub-graph 1 of 15

Citing Papers

Probiotic neoantigen delivery vectors for precision cancer immunotherapy
2024 StandoutNature
Advances in diagnosis and management of cancer of the esophagus
2024 Standout
15 intermediate papers

Works of Dmitry Bichev being referenced

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
2011 Standout
Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts
2011
and 4 more

Author Peers

Author Last Decade Papers Cites
Dmitry Bichev 611 238 340 312 15 660
D.B. Shin 591 266 263 390 17 685
Marco Antônio Gonçalves Rodrigues 588 187 278 353 7 659
Nadine Röthling 486 81 397 310 11 645
Cornelie Haag 472 262 287 109 7 605
Eduardo Viñuela 442 252 291 242 14 581
J.-F. Rey 277 233 410 186 18 582
Jung Ho Shim 480 200 374 108 23 590
Dong‐Seok Han 516 213 359 162 18 694
Junuk Kim 493 265 287 145 14 631
Toshihiro Suematsu 505 291 280 121 16 644

All Works

Loading papers...

Rankless by CCL
2026